KBY Biotech Indexv0.0.34
Search
← Pipeline|TEC-1111

TEC-1111

Phase 1/2
By Bio-Techne
Source: Trial-derived·Trials: 1
Modality
Bispecific Ab
MOA
CDK4/6i
Target
B7-H3
Pathway
Proteasome
LN
Development Pipeline
Preclinical
~Oct 2021
→ ~Jan 2023
Phase 1
Apr 2023
→ Feb 2027
Phase 1Current
NCT03749174
2,799 pts·LN
2023-04→2027-02·Terminated
2,799 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-143mo awayNDA· LN
2027-02-1511mo awayPh2 Data· LN
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P1/2
Termina…
Catalysts
NDA
2026-07-14 · 3mo away
LN
Ph2 Data
2027-02-15 · 11mo away
LN
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03749174Phase 1/2LNTerminated2799SRI-4
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5767PfizerPhase 1/2BETCDK4/6i
LLY-4358Eli LillyPhase 3B7-H3CFTRmod
RHH-1969RocheApprovedBETCDK4/6i
CeviglumideRocheNDA/BLAB7-H3CD47i
IvocapivasertibBristol-Myers SquibbPhase 1BETCDK4/6i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
SNY-8628SanofiNDA/BLAB7-H3TYK2i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
NVO-7840Novo NordiskPhase 2/3B7-H3GLP-1ag